Axsome Therapeutics Inc
(NAS:AXSM)
$
233.8
-15.15 (-6.09%)
Market Cap: 12.03 Bil
Enterprise Value: 11.95 Bil
PE Ratio: 0
PB Ratio: 220.57
GF Score: 52/100 Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022 / 03:40PM GMT
Release Date Price:
$62.27
(+0.32%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Thanks, everyone, for joining. This is a fireside chat with Axsome Therapeutics. Let me read a brief disclosure statement before we get started. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. My name is Vikram Purohit. I'm one of the biotech analysts with the research team. Happy to have with me Herriot Tabuteau, CEO; and Mark Jacobson, COO of Axsome. Thanks for joining us.
Herriot Tabuteau
Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President
Thank you.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
So before we get into any specifics around pipeline Auvelity et cetera. Herriot, do you want to just level set for the audience and just provide a recap of some of the key milestones Axsome through work to do
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot